← Back to Clinical Trials
Recruiting NCT07355634

NCT07355634 Terraflora Daily Care and Gastrointestinal Health

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07355634
Status Recruiting
Phase
Sponsor OvationLab
Condition Gastrointestinal
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-01-12
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Synbiotic Dietary SupplementPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-01-12 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.

Eligibility Criteria

Inclusion Criteria: 1. Adult males or females age ≥ 25 years 2. Ability to read and speak English 3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois) Exclusion Criteria: 1. Daily use within the past month of any probiotic or prebiotic supplement 2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis 3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications 4. Current daily tobacco smoker 5. Known allergies to any substance in the study products 6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol 8. Current participation in another clinical trial 9. Participants unable to provide consent

Contact & Investigator

Central Contact

Chris D'Adamo, Ph.D.

✉ chris@ovationlab.com

📞 240-232-2103

Frequently Asked Questions

Who can join the NCT07355634 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, studying Gastrointestinal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07355634 currently recruiting?

Yes, NCT07355634 is actively recruiting participants. Contact the research team at chris@ovationlab.com for enrollment information.

Where is the NCT07355634 trial being conducted?

This trial is being conducted at Richmond, United States.

Who is sponsoring the NCT07355634 clinical trial?

NCT07355634 is sponsored by OvationLab. The trial plans to enroll 40 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology